HC Wainwright Has Strong Forecast for Genmab A/S Q1 Earnings

Key Points

• HC Wainwright has increased its Q1 2026 earnings estimate for Genmab A/S to $0.34 per share, reflecting growth from a previous forecast of $0.33, affirming a "Buy" rating with a $36.00 price target.
• Truist Financial has also raised its price target for Genmab A/S from $45.00 to $46.00, contributing to a general trend of positive analyst ratings with a consensus rating of "Moderate Buy."
• Genmab A/S reported a $0.54 EPS for the last quarter, exceeding expectations, while the stock has shown a 12-month range between $17.24 and $27.94.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Stock analysts at HC Wainwright increased their Q1 2026 earnings estimates for Genmab A/S in a research note issued on Friday, August 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.34 per share for the quarter, up from their previous estimate of $0.33. HC Wainwright currently has a "Buy" rating and a $36.00 price target on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S's Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.68 EPS, Q4 2026 earnings at $0.75 EPS and FY2026 earnings at $2.38 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The business had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS.

A number of other research firms have also recently commented on GMAB. Truist Financial increased their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a report on Monday, July 28th. Finally, Zacks Research cut shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Genmab A/S has a consensus rating of "Moderate Buy" and a consensus target price of $37.60.

Genmab A/S Price Performance

GMAB traded up $0.09 on Monday, hitting $24.51. 425,511 shares of the stock were exchanged, compared to its average volume of 1,433,276. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $27.94. The business has a 50-day moving average of $21.90 and a two-hundred day moving average of $21.04. The firm has a market capitalization of $15.72 billion, a price-to-earnings ratio of 12.33, a PEG ratio of 6.98 and a beta of 0.95.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in Genmab A/S during the 4th quarter valued at approximately $2,463,000. Barclays PLC increased its position in Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares during the period. NewEdge Advisors LLC increased its position in Genmab A/S by 12.7% during the 4th quarter. NewEdge Advisors LLC now owns 19,304 shares of the company's stock valued at $403,000 after purchasing an additional 2,171 shares during the period. Marshall Wace LLP increased its position in Genmab A/S by 162.2% during the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock valued at $23,422,000 after purchasing an additional 694,243 shares during the period. Finally, First Trust Advisors LP increased its position in Genmab A/S by 18.0% during the 4th quarter. First Trust Advisors LP now owns 1,644,288 shares of the company's stock valued at $34,316,000 after purchasing an additional 251,241 shares during the period. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.